{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
Status:
Investigational
Source:
NCT03406949: Phase 1 Interventional Completed Advanced Solid Tumors
(2018)
Source URL:
Class:
PROTEIN
Status:
Investigational
Source:
NCT03330418: Phase 3 Interventional Recruiting Neuromyelitis Optica Spectrum Disorders
(2018)
Source URL:
Class:
PROTEIN
Status:
Investigational
Source:
NCT04626505: Phase 2 Interventional Completed Chronic Kidney Disease
(2020)
Source URL:
Class:
PROTEIN
Status:
Investigational
Class:
PROTEIN
Status:
Investigational
Source:
INN:crefmirlimab [INN]
Source URL:
Class:
PROTEIN
Status:
Investigational
Source:
NCT02683928: Phase 2 Interventional Completed Atopic Dermatitis
(2016)
Source URL:
Class:
PROTEIN
Status:
Investigational
Source:
INN:mazorelvimab [INN]
Source URL:
Class:
PROTEIN
Status:
Investigational
Source:
NCT02597036: Phase 1 Interventional Completed Solid Tumors
(2015)
Source URL:
Class:
PROTEIN
Status:
Investigational
Source:
NCT03181893: Phase 2 Interventional Completed Dermatomyositis
(2018)
Source URL:
Class:
PROTEIN
Status:
Investigational
Source:
INN:teropavimab [INN]
Source URL:
Class:
PROTEIN
